The solution to drug resistance of Gram-negative bacteria – Cefiderocol
DOI:
https://doi.org/10.12775/JEHS.2023.33.01.002Keywords
cefiderocol, resistance, gram negative bacteriaAbstract
Introduction: A major public health problem is the emergence of anti-gram-negative antimicrobial resistance worldwide. Cefiderocol is a new agent targeting Gram-negative bacteria, including strains with resistance to carbapenems.
Aim of the study: Analysis of the efficiency of cefiderocol in the treatment of infections caused by gram-negative bacteria, the drug's mechanism of action and pharmacokinetics and pharmacodynamics of the drug.
Material and Methods: Search of the PubMed database using the following keywords: cefiderocol, resistance, gram negative bacteria. Only full-length articles were taken into consideration.
Results: The studies show that cefiderocol is active against Enterobacteriaceae, P. aeruginosa, B. cepacia and A. baumannii and effective in the treatment of pneumonia in both non-ventilated and ventilated patients. Moreover, it has been used in the treatment of sepsis as a rescue therapy.
Conclusion: Cefiderocol is an effective treatment for infections caused by gram-negative bacteria. However, more research is needed to learn more about the use of this drug, side effects and resistance mechanisms.
References
Sato, T.; Yamawaki, K. Cefiderocol: Discovery, Chemistry, and In Vivo Profiles of a Novel Siderophore Cephalosporin. Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am. 2019, 69, S538–S543, doi:10.1093/cid/ciz826.
Doi, Y. Treatment Options for Carbapenem-Resistant Gram-Negative Bacterial Infections. Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am. 2019, 69, S565–S575, doi:10.1093/cid/ciz830.
Kanj, S.S.; Bassetti, M.; Kiratisin, P.; Rodrigues, C.; Villegas, M.V.; Yu, Y.; van Duin, D. Clinical Data from Studies Involving Novel Antibiotics to Treat Multidrug-Resistant Gram-Negative Bacterial Infections. Int. J. Antimicrob. Agents 2022, 60, 106633, doi:10.1016/j.ijantimicag.2022.106633.
Kohira, N.; West, J.; Ito, A.; Ito-Horiyama, T.; Nakamura, R.; Sato, T.; Rittenhouse, S.; Tsuji, M.; Yamano, Y. In Vitro Antimicrobial Activity of a Siderophore Cephalosporin, S-649266, against Enterobacteriaceae Clinical Isolates, Including Carbapenem-Resistant Strains. Antimicrob. Agents Chemother. 2016, 60, 729–734, doi:10.1128/AAC.01695-15.
Bilal, M.; El Tabei, L.; Büsker, S.; Krauss, C.; Fuhr, U.; Taubert, M. Clinical Pharmacokinetics and Pharmacodynamics of Cefiderocol. Clin. Pharmacokinet. 2021, 60, 1495–1508, doi:10.1007/s40262-021-01063-5.
Terreni, M.; Taccani, M.; Pregnolato, M. New Antibiotics for Multidrug-Resistant Bacterial Strains: Latest Research Developments and Future Perspectives. Molecules 2021, 26, 2671, doi:10.3390/molecules26092671.
Gijón Cordero, D.; Castillo-Polo, J.A.; Ruiz-Garbajosa, P.; Cantón, R. Antibacterial Spectrum of Cefiderocol. Rev. Espanola Quimioter. Publicacion Of. Soc. Espanola Quimioter. 2022, 35 Suppl 2, 20–27, doi:10.37201/req/s02.03.2022.
Lee, Y.R.; Yeo, S. Cefiderocol, a New Siderophore Cephalosporin for the Treatment of Complicated Urinary Tract Infections Caused by Multidrug-Resistant Pathogens: Preclinical and Clinical Pharmacokinetics, Pharmacodynamics, Efficacy and Safety. Clin. Drug Investig. 2020, 40, 901–913, doi:10.1007/s40261-020-00955-x.
Saisho, Y.; Katsube, T.; White, S.; Fukase, H.; Shimada, J. Pharmacokinetics, Safety, and Tolerability of Cefiderocol, a Novel Siderophore Cephalosporin for Gram-Negative Bacteria, in Healthy Subjects. Antimicrob. Agents Chemother. 2018, 62, e02163-17, doi:10.1128/AAC.02163-17.
Sanabria, C.; Migoya, E.; Mason, J.W.; Stanworth, S.H.; Katsube, T.; Machida, M.; Narukawa, Y.; Den Nagata, T. Effect of Cefiderocol, a Siderophore Cephalosporin, on QT/QTc Interval in Healthy Adult Subjects. Clin. Ther. 2019, 41, 1724-1736.e4, doi:10.1016/j.clinthera.2019.07.006.
Nordmann, P.; Shields, R.K.; Doi, Y.; Takemura, M.; Echols, R.; Matsunaga, Y.; Yamano, Y. Mechanisms of Reduced Susceptibility to Cefiderocol Among Isolates from the CREDIBLE-CR and APEKS-NP Clinical Trials. Microb. Drug Resist. Larchmt. N 2022, 28, 398–407, doi:10.1089/mdr.2021.0180.
Karaba, S.M.; Hirsch, E.B.; Heil, E.L. In a Pinch: Cefiderocol for CRAB Infections. Antimicrob. Agents Chemother. 2022, 66, e0006522, doi:10.1128/aac.00065-22.
Ribeiro, M.; Sousa, C.A.; Simões, M. Harnessing Microbial Iron Chelators to Develop Innovative Therapeutic Agents. J. Adv. Res. 2022, 39, 89–101, doi:10.1016/j.jare.2021.10.010.
Kawaguchi, N.; Katsube, T.; Echols, R.; Wajima, T. Population Pharmacokinetic Analysis of Cefiderocol, a Parenteral Siderophore Cephalosporin, in Healthy Subjects, Subjects with Various Degrees of Renal Function, and Patients with Complicated Urinary Tract Infection or Acute Uncomplicated Pyelonephritis. Antimicrob. Agents Chemother. 2018, 62, e01391-17, doi:10.1128/AAC.01391-17.
Soriano, A.; Pueyo, J.M. Mechanism of Action of Cefiderocol. Rev. Esp. Quimioter. 2022, 35, 16–19.
Katsube, T.; Echols, R.; Wajima, T. Pharmacokinetic and Pharmacodynamic Profiles of Cefiderocol, a Novel Siderophore Cephalosporin. Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am. 2019, 69, S552–S558, doi:10.1093/cid/ciz828.
Maseda, E.; Suárez de la Rica, A. The Role of Cefiderocol in Clinical Practice. Rev. Esp. Quimioter. 2022, 35, 39–44, doi:10.37201/req/s02.06.2022.
Ribeiro, M.; Sousa, C.A.; Simões, M. Harnessing Microbial Iron Chelators to Develop Innovative Therapeutic Agents. J. Adv. Res. 2022, 39, 89–101, doi:10.1016/j.jare.2021.10.010.
Poulakou, G.; Lagou, S.; Karageorgopoulos, D.E.; Dimopoulos, G. New Treatments of Multidrug-Resistant Gram-Negative Ventilator-Associated Pneumonia. Ann. Transl. Med. 2018, 6, 423, doi:10.21037/atm.2018.10.29.
Chumbita, M.; Monzo-Gallo, P.; Lopera-Mármol, C.; Aiello, T.F.; Puerta-Alcalde, P.; Garcia-Vidal, C. New Treatments for Multidrug-Resistant Non-Fermenting Gram-Negative Bacilli Infections. Rev. Esp. Quimioter. 2022, 35 Suppl 3, 51–53, doi:10.37201/req/s03.12.2022.
Matesanz, M.; Mensa, J. Ceftazidime-Avibactam. Rev. Espanola Quimioter. Publicacion Of. Soc. Espanola Quimioter. 2021, 34 Suppl 1, 38–40, doi:10.37201/req/s01.11.2021.
Zhanel, G.G.; Chung, P.; Adam, H.; Zelenitsky, S.; Denisuik, A.; Schweizer, F.; Lagacé-Wiens, P.R.S.; Rubinstein, E.; Gin, A.S.; Walkty, A.; et al. Ceftolozane/Tazobactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination with Activity against Multidrug-Resistant Gram-Negative Bacilli. Drugs 2014, 74, 31–51, doi:10.1007/s40265-013-0168-2.
Gorczyca, K.; Obuchowska, A.; Kimber-Trojnar, Ż.; Wierzchowska-Opoka, M.; Leszczyńska-Gorzelak, B. Changes in the Gut Microbiome and Pathologies in Pregnancy. Int. J. Environ. Res. Public. Health 2022, 19, 9961, doi:10.3390/ijerph19169961.
Saisho, Y.; Katsube, T.; White, S.; Fukase, H.; Shimada, J. Pharmacokinetics, Safety, and Tolerability of Cefiderocol, a Novel Siderophore Cephalosporin for Gram-Negative Bacteria, in Healthy Subjects. Antimicrob. Agents Chemother. 2018, 62, e02163-17, doi:10.1128/AAC.02163-17.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Magdalena Kołodziej, Kamila Gorczyca, Ilona Jastrzębska, Paweł Węgorowski, Michał Wieczorek
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 362
Number of citations: 0
